

Humber Area Prescribing Committee

| | |
|------------------------------|---|
| Date / Time | 3 rd July 2024 13:00-15:00 |
| Venue | MS Teams |
| Chair | Dr Sergio Raise |
| Notes / Action Points | Luke Storr – Senior Pharmacy Technician, HUTH |
| Quorate: Yes / No | No – JM to contact NP outside meeting |

| | |
|-------------------|---|
| Attendance | <p>Dr Sergio Raise, ERY sub-locality GP Prescribing Lead (SR)</p> <p>Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM)</p> <p>Luke Storr – Senior Pharmacy Technician, HUTH (LS)</p> <p>Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK)</p> <p>Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB)</p> <p>Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc)</p> <p>Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH)</p> <p>Joanne Goode – Chief Pharmacist – HUTH (JG)</p> <p>Dr Rolan Schreiber, Medical Secretary LMC (RSc)</p> <p>Prof A Morice, Professor of Respiratory Medicine HUTH- (AM)</p> <p>Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber Foundation Trust (MK)</p> <p>Weeliat Chong, Chief Pharmacist, Humber Teaching NHS Foundation Trust (WC)</p> <p>Marian Opoku-Fofie – Deputy Chief Pharmacist – Humber Teaching NHS Foundation Trust (MOF)</p> <p>Emma Baggaley, Assistant Director Medicines Management (Superintendent Pharmacist), CHCP (EB)</p> <p>Simon Priestley- Chief Pharmacist, NLAG (SP)</p> <p>Natasha Suffill- Lead Clinical Pharmacist CHCP (NS)</p> <p>Dr Pratik Basu- GP- The Birches medical practice (PB)</p> <p>Anna Grocholewska-Mhamdi – Lead Clinical Pharmacist – Navigo (AG)</p> <p>Dr Jeeten Raghvani – GP- Greenlands Surgery (JR)</p> <p>Paula Russell- Principal Pharmacist RDTC (PR) (attending for Daniel Newsome)</p> |
|-------------------|---|

Apologies

Daniel Newsome- Principal Pharmacist RDTC (DN)

Laura Angus- Chief Pharmacy Officer/ Director of Pharmacy and Medicines Optimisation- NHS Humber and North Yorkshire ICB (LA)

Catherine Smith- Senior Medicines Optimisation Pharmacist, NECS (CS)

| Agenda Number | Item | Discussion | Action | Lead | Due Date |
|---------------|-----------------------------|---|---------|----------|----------|
| 2024.07.01 | Apologies | Noted above | | | |
| 2024.07.02 | Declarations of interest | AK declared that he been contacted by a rep for Benilexa | | | |
| 2024.07.03 | Minutes of previous meeting | Accepted as true record | | | |
| 2024.07.04 | Action Tracker | <p>Outstanding actions from NLAPC</p> <p>Funding for SCFs – mycophenolate, modafinil and riluzole (joint SCFs)</p> <p>JM to provide RS information on number of patients in NEL/NL</p> <p>December update: JM provided RS with patient numbers for mycophenolate, modafinil and riluzole</p> <p>February update: RS confirmed SCFs for modafinil and riluzole available within NEL; JM to upload SCFs (riluzole and modafinil for NEL).</p> <p>March update: SCFs uploaded onto Humber APC and linked into formulary. Awaiting NL – RS to update</p> <p>April update: Riluzole to JM to update websites to include NL</p> <p>May update: Riluzole updated, modafinil still waiting for NL, mycophenolate to review</p> <p>June update: Modafanil still waiting on NL, JM to review mycophenolate for July guideline group</p> <p>July update: JM to correct typo and send to RS, JM to review mycophenolate SCF for neurology for September guideline group</p> <p>August update: JM corrected typos, changed over on web and sent to RS, JM still to review mycophenolate SCF for September guideline group</p> <p>September 2023 update: For September guideline group</p> <p>October 2023 update: For November Guideline group</p> <p>November 2023 update: For November Guideline group</p> <p>December 2023 update: For January or March guideline group – to check against York mycophenolate.</p> | Ongoing | JM/RS/CS | 10/24 |

| | | | | | |
|--|--|---|---------|----|-------|
| | | <p>February 2024 update: reviewed against York SCF and contacted neuromuscular lead with national SCF. For March guideline group</p> <p>April 2024 update: RDTC have published reviewed and updated SCF. Neuromuscular lead happy with to update but to do as immunosuppression SCF for all places and specialities that use</p> <p>May 2024 update: SCF update ongoing</p> <p>June 2024 update: SCF update mycophenolate to be removed from here (update to include all indications for MMF) however funding for modafinil not yet resolved.</p> <p>July 2024 update: Modafinil funding for NL ongoing</p> <p>Outstanding actions from HERPC</p> <p>Renal repatriation:</p> <p>November update – JM to meet with renal still; contacted business manager and clinical lead for renal medicine. To update further next time.</p> <p>December update – Not met with renal yet.</p> <p>March update – Updating business case.</p> <p>May update – to meet with NHSE</p> <p>August update – not yet met with NHSE</p> <p>September update: not yet met with NHSE</p> <p>October update: not yet met with NHSE</p> <p>November update: not yet met with NHSE</p> <p>December update: meeting arranged with NHSE</p> <p>February update: meeting arranged and business case in progress</p> <p>April 2024 update: JM and LA met with Paul McManus to discuss further.</p> <p>May 2024 update: business case ongoing</p> <p>July 2024 update: ongoing</p> <p>Blueteq</p> <p>Non-compliance to NICE guidance in acute trusts and financial impact</p> <p>June update: JM to submit ustekinumab report in gastroenterology HUTH when approved</p> <p>JM to present infliximab maintenance and initiation audits in gastroenterology HUTH when completed and approved</p> <p>July update: JM to update next time.</p> <p>August update: no further update, infliximab audit in HUTH started</p> <p>September update: HUTH audits still ongoing</p> | Ongoing | JM | 10/24 |
| | | <p>Blueteq</p> <p>Non-compliance to NICE guidance in acute trusts and financial impact</p> <p>June update: JM to submit ustekinumab report in gastroenterology HUTH when approved</p> <p>JM to present infliximab maintenance and initiation audits in gastroenterology HUTH when completed and approved</p> <p>July update: JM to update next time.</p> <p>August update: no further update, infliximab audit in HUTH started</p> <p>September update: HUTH audits still ongoing</p> | Ongoing | JM | 10/24 |

| | | | | | |
|--|--|--|---------|----|-------|
| | | <p>October update: HUTH audits still ongoing November update: HUTH audits still ongoing December 2023 update: HUTH audits still ongoing, infliximab need more data and started adalimumab audit for homecare patients as recently done brand/provider switch. February 2024 update: Ustekinumab audit outcome form presented which demonstrated compliance with NICE guidance. March 2024 update: Infliximab paper due to presented at April D&TC April 2024 update: HUTH D&TC not until next week to update next time May 2024 update: Infliximab paper presented to HUTH D&TC at last meeting alongside updated guidance (on agenda). HUTH infliximab IBD audit was presented to D&TC and noted multiple dosage regimens are in use. Evaluated cost effectiveness versus current second line agents (vedolizumab or ustekinumab) and escalated infliximab is significantly more cost effective. This will be reviewed as more biosimilar agents become available. July 2024 update: for further discussion at HUTH D&TC as compliance with NICE guidance for red drugs is an internal acute trust issue. Outstanding actions from HERPC: Rheumatology to prepare pathway with rituximab without MTX August update: received NLAG pathway which includes this but not received HUTH pathway. Shared NLAG pathway with Dr Ogumbambi (rheumatology lead in HUTH). Rheumatology pathway for HUTH on D&TC action tracker. To discuss at September D&TC if Dr Ogumbambi in attendance and to contact to confirm place in pathway, to enable JM to start writing paper. September update: September D&TC next week, further updates to pathway needed October update: Awaiting updated pathway November update: Pathway needs further updates as new TAs published again and pharmacist who is updating has prioritised adalimumab switch. December update: ongoing February 2024 update: JG to follow up with Dr Ogumbambi March 2024 update: JG raised at HUTH D&TC; to bring NLAG RA pathway to next guideline group and invite Dr Alvi.</p> | Ongoing | JM | 10/24 |
|--|--|--|---------|----|-------|

| | | | | |
|--|--|-----------------|--------|------|
| | <p>April 2024 update: NLAG RA pathway on agenda May 2024 update: HUTH RA pathway currently circulating rheumatologists for comment. July 2024 update: HUTH RA pathway updates in progress following comments Ratification of guidelines and SCFs: Amiodarone SCF JM to do minor updates and feedback to cardiology team at HUTH; check patient number for NEL/NL from NLAG/HUTH September 2023 update: JM fed back to cardiology team and updated. JM/AK to confirm patient numbers being dispensed at NLAG sites. October 2023 – RS fed back comments from NEL/NL GP leads. JM sent comments to cardiology team. JM confirmed patient numbers from outsourced outpatients at NLAG. November 2023 – to be discussed at next cardiology governance December 2023 - received comments from cardiology JM to review and send to RS/Catherine Smith after review February 2024 update: ongoing March 2024 update: JM to send updated SCF to CS for review. April 2024 update: ongoing May 2024: reviewed and needs reviewing against RDTC documentation. Either back to guideline/SCF group or to APC dependant on number of changes. July 2024: on agenda for next guideline group Feedback from Integrated Medicines Optimisation Committee Sodium valproate prevent compliance December 2023 –RS sent JM audit report and JM fed back to neurologists who state all their patients have annual review and forms. March 2024 update – ICB meetings with stakeholders underway. JM updating HUTH internal policy which will be shared with NLAG. April 2024 update – ICB meetings ongoing. JM meeting with HUTH team to look at internal improvements. June 2024 update – updated SCF on agenda July 2024 update – updated SCF on agenda Work plans To add RDTC SCF to guideline/SCF group to review against local SCFs when published</p> | Ongoing | JM | 9/24 |
| | <p>Feedback from Integrated Medicines Optimisation Committee Sodium valproate prevent compliance December 2023 –RS sent JM audit report and JM fed back to neurologists who state all their patients have annual review and forms. March 2024 update – ICB meetings with stakeholders underway. JM updating HUTH internal policy which will be shared with NLAG. April 2024 update – ICB meetings ongoing. JM meeting with HUTH team to look at internal improvements. June 2024 update – updated SCF on agenda July 2024 update – updated SCF on agenda Work plans To add RDTC SCF to guideline/SCF group to review against local SCFs when published</p> | Ongoing | JM/KMc | 8/24 |
| | <p>Work plans To add RDTC SCF to guideline/SCF group to review against local SCFs when published</p> | Action complete | LS/JM | 7/24 |

| | | | | | |
|--|--|--|---|--|---|
| | | <p>April 2024 update – work ongoing to review SCF workplan. May 2024 update – work in HUTH ongoing July 2024 update – action complete Ratification of guidelines and SCFs To add information around initial supply of devices to erectile dysfunction following prostatectomy guidance April 2024 update: ongoing May 2024: ongoing July 2024: ongoing Ratification of guidelines and SCFs To upload erectile dysfunction following prostatectomy to website and update formulary when uploaded April 2024 update: ongoing May 2024: ongoing July 2024: ongoing RTDC updates To contact local services to discuss update of pathways and providing feedback to APC in timely manner. JM – to contact joint dermatology services hosted by HUTH (TA916), HUTH rheumatology (TA916/TA918/TA920), joint neurology services hosted by HUTH (TA919) and HUTH gastroenterology (TA925) JM to provide OA with HUTH IBD pathway to discuss with clinical lead. OA to contact NLAG gastroenterology(TA925) with HUTH pathway and NLAG rheumatology (TA916/TA918/TA920) March 2024 update: JM contacted dermatology, rheumatology and awaiting updated guidance, JM contacted neurology and updated guidance on agenda, JM contacted gastroenterology and TA925 already within APC approved pathway. OA contacted NLAG gastroenterology with HUTH guidance agreed to review guidance and aim for next version to be joint guidance. OA contacted NLAG rheumatology April 2024 update: ongoing with with gastro to look at merging guidance. JM met with Prof. Sebastian (IBD lead at HUTH) who is happy to liaise with NLAG as they develop their IBD service. June 2024 update: Humber dermatology guidance on agenda. July 2024 update: Action complete (rheumatology pathway outstanding - 02.08.23.05 action from HERPC covers this action) Traffic Light Status</p> | <p>Ongoing</p> <p>Ongoing</p> <p>Action complete</p> <p>Action complete</p> | <p>JM</p> <p>JM</p> <p>JM/OA</p> <p>JM/LS/AK</p> | <p>4/24</p> <p>4/24</p> <p>7/24</p> <p>7/24</p> |
|--|--|--|---|--|---|

| | | | | | |
|------------|----------------------|--|---------------------|----------|------|
| | | To update formulary (netformulary) – action complete Traffic Light Status | Action complete | JM/LS/AK | 7/24 |
| | | To update formulary (HERPC) - action complete Traffic Light Status | | | |
| | | To update red list (HERPC) - action complete Ratification of joint formulary | Action complete | JM/LS/AK | 7/24 |
| | | Update joint formulary with chapter 3 July 2024 update – ongoing Ratification of joint formulary | Ongoing | JM/LS/AK | 9/24 |
| | | Update joint formulary with chapter 11 July 2024 update - ongoing | Ongoing | JM/LS/AK | 9/24 |
| | | RDTC updates | Action complete | JM | 7/24 |
| | | To update formulary/red list Ratification of guidelines and SCFs | | | |
| | | Update front pages of riluzole and verapamil SCF to match new template Ratification of guideline and SCFs | Action complete | JM | 7/24 |
| | | Update front page of dementia SCF and send to MOF Ratification of guidelines and SCFs | Action complete | JM | 7/24 |
| | | Update sick day guidance for type 2 diabetes document title Ratification of guidelines and SCFs | Action complete | JM | 7/24 |
| | | Upload and link approved guidance on Humber APC site (high output stoma and sick day management for type 2 diabetes) Ratification of guidelines and SCFs | Action complete | JM | 7/24 |
| | | Remove old HERPC guidance/SCFs and any legacy links (Verapamil SCF and high output stoma guidance) Ratification of guidelines and SCFs | Action complete | JM | 7/24 |
| | | Upload and link approved pathways on Humber APC site Ratification of guidelines and SCFs | Action complete | JM | 7/24 |
| | | Remove old dermatology pathways from HERPC website Any other business | Action complete | JM | 7/24 |
| | | Update joint formulary workplan with palliative care formulary Any other business | Action complete | JM | 7/24 |
| | | Add testosterone SCF and menopause guidance to next guideline group for review Any other business | Action complete | JM | 7/24 |
| | | Add progesterone pessaries for threatened miscarriage to next joint formulary | Action complete | JM | 7/24 |
| 2024.07.05 | Traffic Light Status | Deucravacitinib (Sotyktu) TA907- Proposed as RED Atogepant (Equipta) TA973- Proposed as AMBER 2, awaiting commissioning position and updated guidance. | To update formulary | JM/LS/AK | 7/24 |

| | | | | | |
|------------|---|---|--|----------|--|
| | | Levonorgestrel 20 micrograms/24 hours (Benilexa® One Handed) – Proposed as PURPLE; APC requests feedback in 6 months to a year. Ketotifen (oral)- remain as RED | | | |
| 2024.07.06 | Feedback from Integrated Medicines Optimisation Committee | <ul style="list-style-type: none"> Private prescribing work ongoing in regards to patients transferring from private care to NHS Ferric Maltol- York and Scarborough Hospitals awaiting decision to use | Noted | | |
| 2024.07.07 | Work plans | <ol style="list-style-type: none"> Joint formulary alignment Shared care frameworks Guidelines | Ongoing for information only | | |
| 2024.07.08 | Topiramate safety update | <ul style="list-style-type: none"> New MHRA safety alert requiring annual risk assessment forms for patients of childbearing potential on topiramate. Different forms and patient information are available dependant on diagnosis (epilepsy versus migraine). | Noted | | |
| 2024.07.09 | Ratification of joint formulary | <ul style="list-style-type: none"> Blood glucose meter formulary (updates) | Approved | | |
| 2024.07.10 | Ratification of guidelines and SCFs | <ol style="list-style-type: none"> Valproate SCF - JM to feedback discussions to CS. | a) Approved | JM | |
| 2024.07.11 | RDTC updates | <ul style="list-style-type: none"> May 2024 | Update formulary/red list | JM/LS/AK | |
| 2024.07.12 | Minutes from subcommittees | <ol style="list-style-type: none"> Joint formulary subcommittee (Nil) Guideline subcommittee (March 24) | Attached for info only | | |
| 2024.07.13 | Additional minutes for information | <ol style="list-style-type: none"> HUTH D&TC (May 24) HFT DTG (Nil) NLAG M&T (Nil) NYA APC (May 24) | Attached for info only | | |
| 2024.07.14 | Correspondence received | Nil this month | | | |
| 2024.07.15 | AOB | <ul style="list-style-type: none"> KMc- Sitagliptin is coming off patent, potential to reevaluate first line choice if cost effective. RSx- GP collective action in talks, proposal to change working ways. GP could change if they wish to accept existing SCFs or future ones | To add to joint formulary agenda and contact diabetes team | | |
| 2024.07.16 | Date of next meeting | 7 th August 2024 13.00 – 15.00 Teams | | | |